메뉴 건너뛰기




Volumn 13, Issue 5, 1999, Pages 647-658

Update on the management of advanced breast cancer

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; ANTIGESTAGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; DOCETAXEL; DOXORUBICIN; EXEMESTANE; FADROZOLE; FORMESTANE; IDOXIFENE; LETROZOLE; LOSOXANTRONE; MEGESTROL ACETATE; MIFEPRISTONE; MONOCLONAL ANTIBODY; PACLITAXEL; PEMETREXED; RALOXIFENE; RECOMBINANT ANTIBODY; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN CITRATE; TAXANE DERIVATIVE; TOREMIFENE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOROZOLE;

EID: 0032984645     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (38)

References (88)
  • 2
    • 0003405566 scopus 로고
    • SEER cancer statistics review 1973-1990
    • Miller B, Ries L, Hankey B (eds): Bethesda, National Institutes of Health
    • Hankey B, Brinton L, Kessler L, et al: SEER cancer statistics review 1973-1990, in Miller B, Ries L, Hankey B (eds): National Institutes of Health Publication, pp 93-278. Bethesda, National Institutes of Health, 1993.
    • (1993) National Institutes of Health Publication , pp. 93-278
    • Hankey, B.1    Brinton, L.2    Kessler, L.3
  • 3
    • 0029981617 scopus 로고    scopus 로고
    • Chemotherapy for advanced breast cancer: A current perspective
    • Seidman AD: Chemotherapy for advanced breast cancer: A current perspective. Semin Oncol 23(suppl 2):55-59, 1996.
    • (1996) Semin Oncol , vol.23 , Issue.2 SUPPL. , pp. 55-59
    • Seidman, A.D.1
  • 4
    • 0001025201 scopus 로고
    • Principles in the management of metastatic disease
    • Harris JR, Henderson IC, Hellman S, et al (eds): Philadelphia, Lippincott
    • Henderson IC, Harris JR: Principles in the management of metastatic disease, in Harris JR, Henderson IC, Hellman S, et al (eds): Breast Diseases, 2nd ed, pp 547-665. Philadelphia, Lippincott, 1991.
    • (1991) Breast Diseases, 2nd Ed , pp. 547-665
    • Henderson, I.C.1    Harris, J.R.2
  • 5
    • 0032423157 scopus 로고    scopus 로고
    • Combination chemotherapy vs single-agent therapy as first- and second-line treatment in metastatic breast cancer: A prospective randomized trial
    • Joensuu H, Holli K, Heikkinen M, et al: Combination chemotherapy vs single-agent therapy as first- and second-line treatment in metastatic breast cancer: A prospective randomized trial. J Clin Oncol 16:3720-3730, 1998.
    • (1998) J Clin Oncol , vol.16 , pp. 3720-3730
    • Joensuu, H.1    Holli, K.2    Heikkinen, M.3
  • 6
    • 0004663288 scopus 로고    scopus 로고
    • Taxotere improves survival over mitomycin-C vinblastine in patients with metastatic breast cancer who have failed an anthracycline-containing regimen: Final results of a phase III randomized trial
    • Nabholtz, JM, Thuerlimann B, Beswoda WR, et al: Taxotere improves survival over mitomycin-C vinblastine in patients with metastatic breast cancer who have failed an anthracycline-containing regimen: Final results of a phase III randomized trial (abstract). Proc Am Soc Clin Oncol 17:101a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Nabholtz, J.M.1    Thuerlimann, B.2    Beswoda, W.R.3
  • 7
    • 0002088796 scopus 로고    scopus 로고
    • Phase III trial of doxorubicin vs paclitaxel vs doxorubicin + paclitaxel as first-line therapy for metastatic breast cancer: An intergroup trial
    • Sledge GW, Neuberg D, Ingle J, et al: Phase III trial of doxorubicin vs paclitaxel vs doxorubicin + paclitaxel as first-line therapy for metastatic breast cancer: An intergroup trial (abstract). Proc Am Soc Clin Oncol 16:1a, 1997.
    • (1997) Proc Am Soc Clin Oncol , vol.16
    • Sledge, G.W.1    Neuberg, D.2    Ingle, J.3
  • 8
    • 0000673570 scopus 로고    scopus 로고
    • Standard vs accelerated intensified CEF in metastatic breast cancer patients: Results from MIG-3 randomized study
    • Lionetto R, Venturini M, Del Mastro L, et al: Standard vs accelerated intensified CEF in metastatic breast cancer patients: Results from MIG-3 randomized study (abstract). Proc Am Soc Oncol 17:111a, 1998.
    • (1998) Proc Am Soc Oncol , vol.17
    • Lionetto, R.1    Venturini, M.2    Del Mastro, L.3
  • 9
    • 0026594645 scopus 로고
    • Autologous bone marrow transplantation for breast cancer
    • Peters WP: Autologous bone marrow transplantation for breast cancer. Curr Opin Oncol 4: 279-282, 1992.
    • (1992) Curr Opin Oncol , vol.4 , pp. 279-282
    • Peters, W.P.1
  • 10
    • 0027732664 scopus 로고
    • High intensity chemotherapy with hematopoietic support in breast cancer
    • Crown J, Vahdat L, Fennelly D, et al: High intensity chemotherapy with hematopoietic support in breast cancer. Ann NY Accad Sci 1:378-388, 1993.
    • (1993) Ann NY Acad Sci , vol.1 , pp. 378-388
    • Crown, J.1    Vahdat, L.2    Fennelly, D.3
  • 11
    • 0029116891 scopus 로고
    • High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial
    • Bezwoda WR, Seymour L, Dansey RD, et al: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483-2489, 1995.
    • (1995) J Clin Oncol , vol.13 , pp. 2483-2489
    • Bezwoda, W.R.1    Seymour, L.2    Dansey, R.D.3
  • 12
    • 26344474783 scopus 로고    scopus 로고
    • Single vs tandem high-dose chemotherapy with stem-cell support for chemotherapy-sensitive metastatic breast cancer: First results from an ongoing multicenter phase III trial
    • Frick M, Kroeger N, Adomeit A, et al: Single vs tandem high-dose chemotherapy with stem-cell support for chemotherapy-sensitive metastatic breast cancer: First results from an ongoing multicenter phase III trial (abstract). Proc Am Soc Clin Oncol 17:141a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Frick, M.1    Kroeger, N.2    Adomeit, A.3
  • 13
    • 26344450003 scopus 로고    scopus 로고
    • Tandem and triple high-dose chemotherapy with autologous peripheral blood stem-cell support in patients with metastatic breast cancer
    • Huober J, Schneeweiss A, Fersis N, et al: Tandem and triple high-dose chemotherapy with autologous peripheral blood stem-cell support in patients with metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 17:146a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Huober, J.1    Schneeweiss, A.2    Fersis, N.3
  • 14
    • 0032529660 scopus 로고    scopus 로고
    • Paclitaxel-induced apoptosis is associated with expression and activation of c-mos gene product in human ovarian carcinoma SKOV3 cells
    • Ling HY, Yang Y, Tornos C, et al: Paclitaxel-induced apoptosis is associated with expression and activation of c-mos gene product in human ovarian carcinoma SKOV3 cells. Cancer Res 58:3633-3640, 1998.
    • (1998) Cancer Res , vol.58 , pp. 3633-3640
    • Ling, H.Y.1    Yang, Y.2    Tornos, C.3
  • 15
    • 0032529464 scopus 로고    scopus 로고
    • Mechanisms of Taxol-induced cell death are concentration dependent
    • Torres K, Horwitz SB: Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 58:3620-3626, 1998.
    • (1998) Cancer Res , vol.58 , pp. 3620-3626
    • Torres, K.1    Horwitz, S.B.2
  • 16
    • 0027238859 scopus 로고
    • Cell kill kinetics and cell cycles effects of Taxol on human and hamster ovarian cell lines
    • Lopes NM, Adams EF, Pitts TW, et al: Cell kill kinetics and cell cycles effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242, 1993.
    • (1993) Cancer Chemother Pharmacol , vol.32 , pp. 235-242
    • Lopes, N.M.1    Adams, E.F.2    Pitts, T.W.3
  • 17
    • 0030020158 scopus 로고    scopus 로고
    • Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death
    • Jordan MA, Wendell K, Gardiner S, et al: Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56:816-825, 1996.
    • (1996) Cancer Res , vol.56 , pp. 816-825
    • Jordan, M.A.1    Wendell, K.2    Gardiner, S.3
  • 18
    • 0029946928 scopus 로고    scopus 로고
    • Ninety-six hour paclitaxel infusion after progression during short taxane exposure: A phase: II pharmacokinetic and pharmacodynamic study in patients with metastatic breast cancer
    • Seidman AD, Hochhauser D, Gollub M, et al: Ninety-six hour paclitaxel infusion after progression during short taxane exposure: A phase: II pharmacokinetic and pharmacodynamic study in patients with metastatic breast cancer. J Clin Oncol 14:1877-1884, 1996.
    • (1996) J Clin Oncol , vol.14 , pp. 1877-1884
    • Seidman, A.D.1    Hochhauser, D.2    Gollub, M.3
  • 19
    • 0029012127 scopus 로고
    • Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease
    • Chang AY, Boros L, Garrow R, et al: Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease. Semin Oncol 22(suppl ):124-127, 1995.
    • (1995) Semin Oncol , vol.22 , Issue.SUPPL. , pp. 124-127
    • Chang, A.Y.1    Boros, L.2    Garrow, R.3
  • 20
    • 8944245005 scopus 로고    scopus 로고
    • Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
    • Nabholtz JM, Gelmon K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996.
    • (1996) J Clin Oncol , vol.14 , pp. 1858-1867
    • Nabholtz, J.M.1    Gelmon, K.2    Bontenbal, M.3
  • 21
    • 0001261990 scopus 로고    scopus 로고
    • Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer - Results from CALGB 9342
    • Winer E, Berry D, Duggan D, et al: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer - results from CALGB 9342 (abstract). Proc Am Soc Clin Oncol 17:101a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Winer, E.1    Berry, D.2    Duggan, D.3
  • 22
    • 0000228951 scopus 로고    scopus 로고
    • Final results: Randomized phase III trial of paclitaxel by 3-hr vs 96-hr infusion in patients with metastatic breast cancer: the long and short of it
    • Holmes FA, Valero V, Buzdar AU, et al: Final results: Randomized phase III trial of paclitaxel by 3-hr vs 96-hr infusion in patients with metastatic breast cancer: The long and short of it (abstract). Proc Am Soc Clin Oncol 17:110a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Holmes, F.A.1    Valero, V.2    Buzdar, A.U.3
  • 23
    • 0000386968 scopus 로고
    • A multicenter randomized study of two schedules of paclitaxel in patients with advanced breast cancer
    • Peretz T, Sulkes A, Chollet P, et al: A multicenter randomized study of two schedules of paclitaxel in patients with advanced breast cancer. Eur J Cancer 31A (suppl 5):S75, 1995.
    • (1995) Eur J Cancer , vol.31 A , Issue.5 SUPPL.
    • Peretz, T.1    Sulkes, A.2    Chollet, P.3
  • 24
    • 0000362869 scopus 로고    scopus 로고
    • Effect of Taxol duration of infusion in advanced breast ca: Results from NSABP-B26 trial comparing 3- to 24-hr infusion of high-dose Taxol
    • Mamounas E, Brown A, Smith R, et al: Effect of Taxol duration of infusion in advanced breast ca: Results from NSABP-B26 trial comparing 3- to 24-hr infusion of high-dose Taxol (abstract). Proc Am Soc Clin Oncol 17:101a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Mamounas, E.1    Brown, A.2    Smith, R.3
  • 25
    • 0031757277 scopus 로고    scopus 로고
    • Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
    • Seidman AD, Hudis CA, Albanel J, et al: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361, 1998.
    • (1998) J Clin Oncol , vol.16 , pp. 3353-3361
    • Seidman, A.D.1    Hudis, C.A.2    Albanel, J.3
  • 26
    • 0027494879 scopus 로고    scopus 로고
    • Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
    • Huizing MT, Keung ACF, Rosing H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:2127-2135, 1997.
    • (1997) J Clin Oncol , vol.11 , pp. 2127-2135
    • Huizing, M.T.1    Keung, A.C.F.2    Rosing, H.3
  • 27
    • 0038313647 scopus 로고    scopus 로고
    • Phase II trial multicenter of a weekly Taxol, 5-fluorouracil and leucovorin regimen in patients with metastatic breast cancer
    • Loesch DM, Robert NJ, Keller AM, et al: Phase II trial multicenter of a weekly Taxol, 5-fluorouracil and leucovorin regimen in patients with metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 17:155a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Loesch, D.M.1    Robert, N.J.2    Keller, A.M.3
  • 28
    • 4243246767 scopus 로고    scopus 로고
    • Losoxantrone + paclitaxel vs paclitaxel alone as first-line chemotherapy for metastatic breast cancer: Final results of a phase III randomized trial
    • Kaufman PA, Harris R, Skillings J, et al: Losoxantrone + paclitaxel vs paclitaxel alone as first-line chemotherapy for metastatic breast cancer: Final results of a phase III randomized trial (abstract). Proc Am Soc Clin Oncol 17:124a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Kaufman, P.A.1    Harris, R.2    Skillings, J.3
  • 29
    • 0001452492 scopus 로고    scopus 로고
    • Activity of weekly Taxotere in patients with metastatic breast cancer
    • Loeffler TM, Freund W, Droege C, et al: Activity of weekly Taxotere in patients with metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 17:113a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Loeffler, T.M.1    Freund, W.2    Droege, C.3
  • 30
    • 0000677325 scopus 로고    scopus 로고
    • Taxotere vs methotrexate-5-fluorouracil in patients with advanced anthracycline-resistant breast cancer: Preliminary results of a randomized phase III study by Scandinavian Breast Cancer Group
    • Sjöström J, Mouridsen H, Pluzanska A, et al: Taxotere vs methotrexate-5-fluorouracil in patients with advanced anthracycline-resistant breast cancer: Preliminary results of a randomized phase III study by Scandinavian Breast Cancer Group (abstract). Proc Am Soc Clin Oncol 17:111a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Sjöström, J.1    Mouridsen, H.2    Pluzanska, A.3
  • 31
    • 0000972173 scopus 로고    scopus 로고
    • A multicenter phase II trial of Xeloda (capecitabine) in paclitaxel-refractory metastatic breast cancer
    • Blum JL, Buzdar AU, LoRusso PM, et al: A multicenter phase II trial of Xeloda (capecitabine) in paclitaxel-refractory metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 17:125a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Blum, J.L.1    Buzdar, A.U.2    LoRusso, P.M.3
  • 32
    • 0000709431 scopus 로고    scopus 로고
    • A randomized phase II study of Xeloda (capecitabine) vs CMF as first-line chemotherapy of breast cancer in women aged ≥ 55 years (abstract)
    • O' Shaughnessy J, Moiseyenko V, Bell D, et al: A randomized phase II study of Xeloda (capecitabine) vs CMF as first-line chemotherapy of breast cancer in women aged ≥ 55 years (abstract). Proc Am Soc Clin Oncol 17:103a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • O' Shaughnessy, J.1    Moiseyenko, V.2    Bell, D.3
  • 33
    • 0001432831 scopus 로고    scopus 로고
    • A randomized phase II study of Xeloda (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy (abstract)
    • O' Reilly SM, Moiseyenko V, Talbot DC, et al: A randomized phase II study of Xeloda (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy (abstract). Proc Am Soc Clin Oncol 17:163a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • O' Reilly, S.M.1    Moiseyenko, V.2    Talbot, D.C.3
  • 34
    • 4244031466 scopus 로고    scopus 로고
    • Synergistic efficacy of Xeloda (capecitabine), a new oral tumor-activated fluoropyrimidine carbamate in combination with taxanes and with 2′-deoxy-2′-methylidenecytidine
    • Ishikawa T, Sawada N, Sekiguchi F, et al: Synergistic efficacy of Xeloda (capecitabine), a new oral tumor-activated fluoropyrimidine carbamate in combination with taxanes and with 2′-deoxy-2′-methylidenecytidine (abstract). Proc Am Soc Clin Oncol 17:244a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Ishikawa, T.1    Sawada, N.2    Sekiguchi, F.3
  • 35
    • 0001293608 scopus 로고    scopus 로고
    • Decreased cardiac toxicity by TLC D-99 (liposome encapsulated doxorubicin) vs doxorubicin in a randomized trial of metastatic breast carcinoma
    • Batist G, Winer E, Navari R, et al: Decreased cardiac toxicity by TLC D-99 (liposome encapsulated doxorubicin) vs doxorubicin in a randomized trial of metastatic breast carcinoma (abstract). Proc Am Soc Clin Oncol 17:115a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Batist, G.1    Winer, E.2    Navari, R.3
  • 36
    • 0004570541 scopus 로고    scopus 로고
    • Phase II randomized study of BMS-182248-1 (BR96-doxorubicin immunoconjugate) vs single-agent doxorubicin in patients with metastatic breast cancer
    • Tolcher A, Sugarman S, Gelmon K: Phase II randomized study of BMS-182248-1 (BR96-doxorubicin immunoconjugate) vs single-agent doxorubicin in patients with metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 17:113a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Tolcher, A.1    Sugarman, S.2    Gelmon, K.3
  • 37
    • 0001045163 scopus 로고    scopus 로고
    • Phase II study of MTA (LY 231514) in patients with locally recurrent or metastatic breast cancer
    • Lind MJ, Smith IE, Coleman RE: Phase II study of MTA (LY 231514) in patients with locally recurrent or metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 17:112a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Lind, M.J.1    Smith, I.E.2    Coleman, R.E.3
  • 38
    • 0002529003 scopus 로고    scopus 로고
    • A phase I study of marimistat in combination with doxorubicin and cyclophosphamide in patients with metastatic breast cancer
    • Gradishar W, Sparano J, Cobleigh M, et al: A phase I study of marimistat in combination with doxorubicin and cyclophosphamide in patients with metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 17:144a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Gradishar, W.1    Sparano, J.2    Cobleigh, M.3
  • 39
    • 50549123220 scopus 로고
    • On the treatment of inoperable cases of carcinomas of the mamma: Suggestions for a new method of treatment, with illustrative cases
    • Beatson GT: On the treatment of inoperable cases of carcinomas of the mamma: Suggestions for a new method of treatment, with illustrative cases. Lancet 2:104, 1896.
    • (1896) Lancet , vol.2 , pp. 104
    • Beatson, G.T.1
  • 40
    • 0031054478 scopus 로고    scopus 로고
    • Tamoxifen as initial endocrine therapy for metastatic breast cancer: Long-term follow-up of two Piedmont Oncology Association (POA) trials
    • Kuss JT, Muss HB, Hoen H, et al: Tamoxifen as initial endocrine therapy for metastatic breast cancer: Long-term follow-up of two Piedmont Oncology Association (POA) trials. Breast Cancer Res Treat 42:265-274, 1997.
    • (1997) Breast Cancer Res Treat , vol.42 , pp. 265-274
    • Kuss, J.T.1    Muss, H.B.2    Hoen, H.3
  • 41
    • 0020659444 scopus 로고
    • Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer
    • Tormey DC, Lippman ME, Edwards BK, et al: Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med 98:139-144, 1983.
    • (1983) Ann Intern Med , vol.98 , pp. 139-144
    • Tormey, D.C.1    Lippman, M.E.2    Edwards, B.K.3
  • 42
    • 0015915672 scopus 로고
    • Anti-oestrogen therapy for breast cancer: A trial of tamoxifen at two dose levels
    • Ward HW: Anti-oestrogen therapy for breast cancer: A trial of tamoxifen at two dose levels. Br Med J 1:13-14, 1973.
    • (1973) Br Med J , vol.1 , pp. 13-14
    • Ward, H.W.1
  • 43
    • 0021141476 scopus 로고
    • A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bid vs 20 mg bid
    • Bratherton DG, Brown CH, Buchanan R, et al: A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bid vs 20 mg bid. Br J Cancer 50:199-205, 1984.
    • (1984) Br J Cancer , vol.50 , pp. 199-205
    • Bratherton, D.G.1    Brown, C.H.2    Buchanan, R.3
  • 44
    • 0021269031 scopus 로고
    • Venous thrombosis as a side effect of tamoxifen treatment
    • Lipton A, Harvey HA, Hamilton RW: Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 68:887-889, 1984.
    • (1984) Cancer Treat Rep , vol.68 , pp. 887-889
    • Lipton, A.1    Harvey, H.A.2    Hamilton, R.W.3
  • 45
    • 0020398315 scopus 로고
    • Tamoxifen and oophorectomy in the treatment of recurrent breast cancer: A Southwest Oncology Group study
    • Hoogstraten B, Fletcher WS, Gad-el-Mawla N, et al: Tamoxifen and oophorectomy in the treatment of recurrent breast cancer: A Southwest Oncology Group study. Cancer Res 42:4788-4791, 1982.
    • (1982) Cancer Res , vol.42 , pp. 4788-4791
    • Hoogstraten, B.1    Fletcher, W.S.2    Gad-El-Mawla, N.3
  • 46
    • 0022617734 scopus 로고
    • Randomized trial of bilateral oophorectomy vs tamoxifen in premenopausal women with metastatic breast cancer
    • Ingle JN, Krook JE, Green SJ, et al: Randomized trial of bilateral oophorectomy vs tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4:178-185, 1986.
    • (1986) J Clin Oncol , vol.4 , pp. 178-185
    • Ingle, J.N.1    Krook, J.E.2    Green, S.J.3
  • 47
    • 0022554059 scopus 로고
    • A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer
    • Buchanan RB, Blarney RW, Durrant KR, et al: A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4:1326-1330, 1986.
    • (1986) J Clin Oncol , vol.4 , pp. 1326-1330
    • Buchanan, R.B.1    Blarney, R.W.2    Durrant, K.R.3
  • 48
    • 0030787363 scopus 로고    scopus 로고
    • A randomized crossover trial of tamoxifen vs ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA. 1
    • Sawka CA, Pritchard KI, Shelley W, et al: A randomized crossover trial of tamoxifen vs ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA. 1. Breast Cancer Res Treat 44:211-215, 1997.
    • (1997) Breast Cancer Res Treat , vol.44 , pp. 211-215
    • Sawka, C.A.1    Pritchard, K.I.2    Shelley, W.3
  • 49
    • 0030876075 scopus 로고    scopus 로고
    • An individual patient-based meta-analysis of tamoxifen vs ovarian ablation as first-line endocrine therapy for premenopausal women with metastatic breast cancer
    • Crump M, Sawka CA, DeBoer G, et al: An individual patient-based meta-analysis of tamoxifen vs ovarian ablation as first-line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat 44:201-210, 1997.
    • (1997) Breast Cancer Res Treat , vol.44 , pp. 201-210
    • Crump, M.1    Sawka, C.A.2    DeBoer, G.3
  • 50
    • 0028274195 scopus 로고
    • Ovarian ablation vs goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: Results of a multicentric Italian study
    • Boccardo F, Rubagotti A, Perrotta A, et al: Ovarian ablation vs goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: Results of a multicentric Italian study. Ann Oncol 5:337-342, 1994.
    • (1994) Ann Oncol , vol.5 , pp. 337-342
    • Boccardo, F.1    Rubagotti, A.2    Perrotta, A.3
  • 51
    • 0031471007 scopus 로고    scopus 로고
    • Acquired tamoxifen resistance in human breast cancer - Potential mechanisms and clinical implications
    • Johnston SR: Acquired tamoxifen resistance in human breast cancer - potential mechanisms and clinical implications. Anticancer Drugs 8:911-930, 1997.
    • (1997) Anticancer Drugs , vol.8 , pp. 911-930
    • Johnston, S.R.1
  • 53
    • 0031962302 scopus 로고    scopus 로고
    • Tamoxifen and toremifene in breast cancer: Comparison of safety and efficacy
    • Buzdar AU, Hortobagyi GN: Tamoxifen and toremifene in breast cancer: Comparison of safety and efficacy. J Clin Oncol 16:348-353, 1998.
    • (1998) J Clin Oncol , vol.16 , pp. 348-353
    • Buzdar, A.U.1    Hortobagyi, G.N.2
  • 54
    • 2642657654 scopus 로고    scopus 로고
    • Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: A randomized double-blind, the 'Nordic' phase III study
    • Pyrhonen S, Valavaara R, Modig H, et al: Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: A randomized double-blind, the 'Nordic' phase III study. Br J Cancer 76:270-277, 1997.
    • (1997) Br J Cancer , vol.76 , pp. 270-277
    • Pyrhonen, S.1    Valavaara, R.2    Modig, H.3
  • 55
    • 0029084658 scopus 로고
    • Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer
    • Hayes DF, Van Zyl JA, Hacking A, et al: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13:2556-2566, 1995.
    • (1995) J Clin Oncol , vol.13 , pp. 2556-2566
    • Hayes, D.F.1    Van Zyl, J.A.2    Hacking, A.3
  • 56
    • 0030993064 scopus 로고    scopus 로고
    • High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer
    • Gershanovich M, Hayes DF, Ellmen J, et al: High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer. Oncology 11:29-36, 1997.
    • (1997) Oncology , vol.11 , pp. 29-36
    • Gershanovich, M.1    Hayes, D.F.2    Ellmen, J.3
  • 57
    • 0027463002 scopus 로고
    • Toremifene and tamoxifen in advanced breast cancer - A double-blind cross-over trial
    • Stenbygaard LE, Herrstedt J, Thomsen JF, et al: Toremifene and tamoxifen in advanced breast cancer - A double-blind cross-over trial. Breast Cancer Res Treat 25:57-63, 1993.
    • (1993) Breast Cancer Res Treat , vol.25 , pp. 57-63
    • Stenbygaard, L.E.1    Herrstedt, J.2    Thomsen, J.F.3
  • 58
    • 0026763121 scopus 로고
    • Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: Preliminary results of a double-blind dose-finding phase II trial
    • Bruning PF: Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: Preliminary results of a double-blind dose-finding phase II trial. Eur J Cancer 28A:1404-1407, 1992.
    • (1992) Eur J Cancer , vol.28 A , pp. 1404-1407
    • Bruning, P.F.1
  • 59
    • 0026337142 scopus 로고
    • European early phase II dose-finding study of droloxifene in advanced breast cancer
    • Bellmunt J, Sole L: European early phase II dose-finding study of droloxifene in advanced breast cancer. Am J Clin Oncol 14 (suppl 2):S36-39, 1991.
    • (1991) Am J Clin Oncol , vol.14 , Issue.2 SUPPL.
    • Bellmunt, J.1    Sole, L.2
  • 60
    • 0030016280 scopus 로고    scopus 로고
    • Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer
    • Howell A, DeFriend DJ, Robertson JF, et al: Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 74:300-308, 1996.
    • (1996) Br J Cancer , vol.74 , pp. 300-308
    • Howell, A.1    DeFriend, D.J.2    Robertson, J.F.3
  • 61
    • 0002258194 scopus 로고    scopus 로고
    • Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women: Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial
    • Cummings SR, Norton L, Eckert S, et al: Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women: Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial (abstract). Proc Am Soc Clin Oncol 17:2a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Cummings, S.R.1    Norton, L.2    Eckert, S.3
  • 62
    • 0025036312 scopus 로고
    • Second-line hormonal therapy with aminoglutethimide in metastatic breast cancer
    • Brufman G, Biran S: Second-line hormonal therapy with aminoglutethimide in metastatic breast cancer. Acta Oncol 29:717-720, 1990.
    • (1990) Acta Oncol , vol.29 , pp. 717-720
    • Brufman, G.1    Biran, S.2
  • 63
    • 9244245282 scopus 로고    scopus 로고
    • A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer
    • Jonat W, Howell A, Blomqvist C, et al: A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A:404-412, 1996.
    • (1996) Eur J Cancer , vol.32 A , pp. 404-412
    • Jonat, W.1    Howell, A.2    Blomqvist, C.3
  • 64
    • 0031054095 scopus 로고    scopus 로고
    • A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma: Arimidex Study Group
    • Buzdar AU, Jones SE, Vogel CL, et al: A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma: Arimidex Study Group. Cancer 79:730-739, 1997.
    • (1997) Cancer , vol.79 , pp. 730-739
    • Buzdar, A.U.1    Jones, S.E.2    Vogel, C.L.3
  • 65
    • 0032530988 scopus 로고    scopus 로고
    • Anastrozole vs megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials: Arimidex Study Group
    • Buzdar AU, Jonat W, Howell A, et al: Anastrozole vs megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials: Arimidex Study Group. Cancer 83:1142-1152, 1998.
    • (1998) Cancer , vol.83 , pp. 1142-1152
    • Buzdar, A.U.1    Jonat, W.2    Howell, A.3
  • 66
    • 0031943424 scopus 로고    scopus 로고
    • Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
    • Dombernowsky P, Smith I, Falkson G, et al: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461, 1998.
    • (1998) J Clin Oncol , vol.16 , pp. 453-461
    • Dombernowsky, P.1    Smith, I.2    Falkson, G.3
  • 67
    • 0038478620 scopus 로고    scopus 로고
    • First-line fadrozole HCI (CGS 16949A) vs tamoxifen in postmenopausal women with advanced breast cancer: Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88
    • Thurlimann B, Beretta K, Bacchi M, et al: First-line fadrozole HCI (CGS 16949A) vs tamoxifen in postmenopausal women with advanced breast cancer: Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol 7:471-479, 1996.
    • (1996) Ann Oncol , vol.7 , pp. 471-479
    • Thurlimann, B.1    Beretta, K.2    Bacchi, M.3
  • 68
    • 0029940269 scopus 로고    scopus 로고
    • Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials
    • Buzdar AU, Smith R, Vogel C, et al: Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials. Cancer 77:2503-2513, 1996.
    • (1996) Cancer , vol.77 , pp. 2503-2513
    • Buzdar, A.U.1    Smith, R.2    Vogel, C.3
  • 69
    • 0003354802 scopus 로고    scopus 로고
    • Vorozole vs Megace in postmenopausal patients with metastatic breast carcinoma who had relapsed following tamoxifen
    • Goss P, Wine E, Tannock I, et al: Vorozole vs Megace in postmenopausal patients with metastatic breast carcinoma who had relapsed following tamoxifen (abstract). Proc Am Soc Clin Oncol 16:A542, 1997.
    • (1997) Proc Am Soc Clin Oncol , vol.16
    • Goss, P.1    Wine, E.2    Tannock, I.3
  • 70
    • 0343924363 scopus 로고    scopus 로고
    • Formestane vs megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: A phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90): Swiss Group for Clinical Cancer Research (SAKK)
    • Thurlimann B, Castiglione M, Hsu-Schmitz SF, et al: Formestane vs megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: A phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90): Swiss Group for Clinical Cancer Research (SAKK). Eur J Cancer 33:1017-1024, 1997.
    • (1997) Eur J Cancer , vol.33 , pp. 1017-1024
    • Thurlimann, B.1    Castiglione, M.2    Hsu-Schmitz, S.F.3
  • 71
    • 0029739075 scopus 로고    scopus 로고
    • Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: A National Cancer Institute of Canada Clinical Trials Group study
    • Perrault D, Eisenhauer EA, Pritchard KI, et al: Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: A National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 14:2709-2712, 1996.
    • (1996) J Clin Oncol , vol.14 , pp. 2709-2712
    • Perrault, D.1    Eisenhauer, E.A.2    Pritchard, K.I.3
  • 72
    • 0026025755 scopus 로고
    • Growth factors in development, transformation, and tumorigenesis
    • Cross M, Dexter TM: Growth factors in development, transformation, and tumorigenesis. Cell 64:271-80, 1991.
    • (1991) Cell , vol.64 , pp. 271-280
    • Cross, M.1    Dexter, T.M.2
  • 73
    • 0022588467 scopus 로고
    • Similarity of protein encoded by the human c-erb B-2 gene to epidermal growth factor receptor
    • Yamamoto T, Ikawa S, Akiyama T, et al: Similarity of protein encoded by the human c-erb B-2 gene to epidermal growth factor receptor. Nature 319:230-234, 1986.
    • (1986) Nature , vol.319 , pp. 230-234
    • Yamamoto, T.1    Ikawa, S.2    Akiyama, T.3
  • 74
    • 0022600388 scopus 로고
    • The neu oncogene encodes an epidermal growth factor receptor-related protein
    • Bargman CJ, Hung MC, Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226-230, 1986.
    • (1986) Nature , vol.319 , pp. 226-230
    • Bargman, C.J.1    Hung, M.C.2    Weinberg, R.A.3
  • 75
    • 0024337144 scopus 로고
    • Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    • Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989.
    • (1989) Science , vol.244 , pp. 707-712
    • Slamon, D.J.1    Godolphin, W.2    Jones, L.A.3
  • 76
    • 37049183697 scopus 로고
    • Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
    • Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987.
    • (1987) Science , vol.235 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3
  • 77
    • 0024360141 scopus 로고
    • Her-2/neu oncogene protein and prognosis in breast cancer
    • Tandon AK, Clark GM, Chamness GC, et al: Her-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7: 1120-1128, 1989.
    • (1989) J Clin Oncol , vol.7 , pp. 1120-1128
    • Tandon, A.K.1    Clark, G.M.2    Chamness, G.C.3
  • 78
    • 0026625217 scopus 로고
    • Prognostic importance of c-erb B-2 expression in breast cancer
    • Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erb B-2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992.
    • (1992) J Clin Oncol , vol.10 , pp. 1049-1056
    • Gusterson, B.A.1    Gelber, R.D.2    Goldhirsch, A.3
  • 79
    • 0029991439 scopus 로고    scopus 로고
    • Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer
    • Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996.
    • (1996) J Clin Oncol , vol.14 , pp. 737-744
    • Baselga, J.1    Tripathy, D.2    Mendelsohn, J.3
  • 80
    • 0000905158 scopus 로고    scopus 로고
    • Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer
    • Cobleigh MA, Vogel CL, Tripathy D, et al: Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 17:91a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Cobleigh, M.A.1    Vogel, C.L.2    Tripathy, D.3
  • 81
    • 0000405942 scopus 로고    scopus 로고
    • Addition of Herceptin (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized, multinational controlled phase III trial
    • Slamon D, Leyland-Jones B, Shak S, et al: Addition of Herceptin (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized, multinational controlled phase III trial (abstract). Proc Am Soc Clin Oncol 17:98a, 1998.
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Slamon, D.1    Leyland-Jones, B.2    Shak, S.3
  • 82
    • 0032127350 scopus 로고    scopus 로고
    • Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
    • Baselga J, Norton L, Albanell J, et al: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825-2831, 1998.
    • (1998) Cancer Res , vol.58 , pp. 2825-2831
    • Baselga, J.1    Norton, L.2    Albanell, J.3
  • 83
    • 0003304702 scopus 로고    scopus 로고
    • Characterization of cardiac dysfunction observed in the Herceptin (trastuzumab) clinical trials
    • Hudis C, Seidman A, Paton V, et al: Characterization of cardiac dysfunction observed in the Herceptin (trastuzumab) clinical trials (abstract). Breast Cancer Res Treat 50(3):232, 1998.
    • (1998) Breast Cancer Res Treat , vol.50 , Issue.3 , pp. 232
    • Hudis, C.1    Seidman, A.2    Paton, V.3
  • 84
    • 0019847618 scopus 로고
    • Tamoxifen vs aminoglutethimide in advanced breast carcinoma: A randomized cross-over trial
    • Smith IE, Harris AL, Morgan M, et al: Tamoxifen vs aminoglutethimide in advanced breast carcinoma: A randomized cross-over trial. Br J Med 283:1432-1434, 1981.
    • (1981) Br J Med , vol.283 , pp. 1432-1434
    • Smith, I.E.1    Harris, A.L.2    Morgan, M.3
  • 85
    • 0019382847 scopus 로고
    • Randomized clinical trial of diethylstilbestrol vs tamoxifen in postmenopausal women with advanced breast cancer
    • Ingle JN, Ahmann DL, Green SJ, et al: Randomized clinical trial of diethylstilbestrol vs tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304:16-21, 1981.
    • (1981) N Engl J Med , vol.304 , pp. 16-21
    • Ingle, J.N.1    Ahmann, D.L.2    Green, S.J.3
  • 86
    • 85036438369 scopus 로고
    • Tamoxifen vs high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: A Piedmont Oncology Association study
    • Muss HB, Case LD, Atkins JN, et al: Tamoxifen vs high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: A Piedmont Oncology Association study. J Clin Oncol 6:1098-1106, 1988.
    • (1988) J Clin Oncol , vol.6 , pp. 1098-1106
    • Muss, H.B.1    Case, L.D.2    Atkins, J.N.3
  • 87
    • 0024041157 scopus 로고
    • Megestrol acetate versus tamoxifen in advanced breast cance, 5-year analysis - A phase III trial of the Piedmont Oncology Association
    • Muss HB, Wells HB, Paschold EH, et al: Megestrol acetate versus tamoxifen in advanced breast cance, 5-year analysis - a phase III trial of the Piedmont Oncology Association. J Clin Oncol 6:1098-1106, 1988.
    • (1988) J Clin Oncol , vol.6 , pp. 1098-1106
    • Muss, H.B.1    Wells, H.B.2    Paschold, E.H.3
  • 88
    • 0028131860 scopus 로고
    • Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer
    • Perez Carrion R, Alberola Candel V, Calabresi F, et al: Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 5 (suppl 7):S19-24, 1994.
    • (1994) Ann Oncol , vol.5 , Issue.7 SUPPL.
    • Perez Carrion, R.1    Alberola Candel, V.2    Calabresi, F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.